Abdiasis Yalahow1, Jill Doctoroff2, Alice Mark3, Angel M Foster4. 1. Faculty of Health Sciences, University of Ottawa, ON, Canada. 2. National Abortion Federation Canada, Vancouver, BC, Canada. 3. National Abortion Federation, Washington, DC, USA. 4. Faculty of Health Sciences, University of Ottawa, ON, Canada; Institute of Population Health, University of Ottawa, Ottawa, ON, Canada. Electronic address: angel.foster@uottawa.ca.
Abstract
OBJECTIVE: We analyzed trends in medication abortion provision before and after the 2017 introduction of mifepristone in Canada. METHODS: We reviewed 2016-2018 abortion services data from Canadian members of the National Abortion Federation (NAF) to determine the overall proportion of medication abortions in each calendar year as well as temporal and geographic trends in provision. RESULTS: In 2016, NAF's Canadian members reported on 33,857 abortions of which 2,844 (8.4%) were with medications and used a methotrexate/misoprostol regimen. In 2018, 8,534 (25.6%) of the 33,320 reported abortions were with mifepristone/misoprostol. DISCUSSION: Mifepristone/misoprostol has been rapidly incorporated into abortion services in Canada.
OBJECTIVE: We analyzed trends in medication abortion provision before and after the 2017 introduction of mifepristone in Canada. METHODS: We reviewed 2016-2018 abortion services data from Canadian members of the National Abortion Federation (NAF) to determine the overall proportion of medication abortions in each calendar year as well as temporal and geographic trends in provision. RESULTS: In 2016, NAF's Canadian members reported on 33,857 abortions of which 2,844 (8.4%) were with medications and used a methotrexate/misoprostol regimen. In 2018, 8,534 (25.6%) of the 33,320 reported abortions were with mifepristone/misoprostol. DISCUSSION: Mifepristone/misoprostol has been rapidly incorporated into abortion services in Canada.